About Endotis Pharma
Endotis Pharma is a company based in Romainville (France) founded in 2003. Endotis Pharma has raised $41.13 million across 2 funding rounds from investors including Wellcome, Endeavour Vision and Sofinnova. Endotis Pharma operates in a competitive market with competitors including Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
- Headquarter Romainville, France
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Jurisdiction Bangalore North, Karnataka, India
-
Annual Revenue
$403.09 K (USD)19.31as on Mar 31, 2022
-
Net Profit
$26.11 K (USD)-14.87as on Mar 31, 2022
-
EBITDA
$31.2 K (USD)28.43as on Mar 31, 2022
-
Total Equity Funding
$41.13 M (USD)
in 2 rounds
-
Latest Funding Round
$36.22 M (USD), Series B
Jan 23, 2008
-
Investors
Wellcome
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Endotis Pharma
Endotis Pharma has successfully raised a total of $41.13M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $36.22 million completed in January 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Endotis Pharma
Endotis Pharma has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Wellcome, Endeavour Vision and Sofinnova.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Endeavour Vision is focused on transformative healthcare technology investments.
|
Locked | Locked | Locked | |
|
Life Sciences sector focused early stage VC firm investing primarily in Europe
|
Locked | Locked | Locked | |
|
Wellcome is a global charitable foundation focused on health research.
|
Locked | Locked | Locked |
Investor details for Endotis Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Endotis Pharma
Investment portfolio details for Endotis Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Endotis Pharma
Detailed financials for Endotis Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Endotis Pharma Comparisons
Peer comparison for Endotis Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Endotis Pharma
Endotis Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
Specialized drugs are developed for genetic heart diseases.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed.
|
Detailed competitors of Endotis Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Endotis Pharma
Complete news archive for Endotis Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Endotis Pharma
Endotis Pharma was founded in 2003 and raised its 1st funding round 2 years after it was founded.
Endotis Pharma is headquartered in Romainville, France. It is registered at Romainville, Ile-de-france, France.
Endotis Pharma is a funded company, having raised a total of $41.13M across 2 funding rounds to date.
Annual revenue of Endotis Pharma is $403.09K as on Mar 31, 2022.
As of October 25, 2012, Endotis Pharma SA is in liquidation. The company specialized in the discovery and development of small glycan drugs (SGDs) for cardiovascular diseases. The company also discovers and develops small-glyco drugs for applications in thrombosis, oncology, and hematology. Through internal research and in-licensing, Endotis had developed a pipeline including EP217609, a neutralizable anticoagulant for managing extracorporeal blood circulation during open-heart surgery; fondaparinux (Arixtra), a reference injectable drug for the prevention and treatment of venous thromboembolism; and an oral antidotable anticoagulant for stroke prevention in atrial fibrillation.
Endotis Pharma's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.
Endotis Pharma has 3 investors. Key investors include Wellcome, Endeavour Vision, and Sofinnova.